Advertisement
Canada markets open in 7 hours 35 minutes
  • S&P/TSX

    21,837.18
    -12.02 (-0.06%)
     
  • S&P 500

    5,149.42
    +32.33 (+0.63%)
     
  • DOW

    38,790.43
    +75.63 (+0.20%)
     
  • CAD/USD

    0.7373
    -0.0016 (-0.22%)
     
  • CRUDE OIL

    82.49
    -0.23 (-0.28%)
     
  • Bitcoin CAD

    88,135.17
    -5,058.33 (-5.43%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,161.80
    -2.50 (-0.12%)
     
  • RUSSELL 2000

    2,024.74
    -14.58 (-0.72%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • NASDAQ futures

    18,188.50
    -43.00 (-0.24%)
     
  • VOLATILITY

    14.33
    -0.08 (-0.56%)
     
  • FTSE

    7,722.55
    -4.87 (-0.06%)
     
  • NIKKEI 225

    39,912.28
    +171.88 (+0.43%)
     
  • CAD/EUR

    0.6784
    -0.0008 (-0.12%)
     

Top biotech investor says Trump's criticism of Pfizer is scaring drug companies from raising prices

Sarissa Capital Management chief investment officer Alex Denner believes President Donald Trump’s criticism of Pfizer is having an impact on how other companies set their prices. “By putting pressure on one particular company, I think all the companies are saying: We don’t want to be Pfizer,” Denner said at the Delivering Alpha Conference. Trump bashed Pfizer and other drugmakers for raising the price of 104 different drugs, arguing that such companies “should be ashamed” for the hikes.